Psychedelic mushrooms, primarily species of the genus Psilocybe, have been used for thousands of years for their hallucinogenic effects.
However, in recent years, their therapeutic potential has sparked growing interest within the scientific community. Renowned experts such as Dr. Roland Griffiths of Johns Hopkins University, Dr. Robin Carhart-Harris of Imperial College London, and Dr. Matthew Johnson, also of Johns Hopkins University, have been at the forefront of research on psychedelics.
This research paves the way for a new understanding of potential treatments for conditions such as depression, addiction, and other mental disorders that are resistant to conventional treatments.
This article explores the history, traditional uses, and ethical and legal issues surrounding these mushrooms, with a particular focus on their potential role in treating addiction and depression. We will also examine other psychedelic mushrooms, such as the fly agaric (Amanita muscaria), and their use in various cultures around the world.
1. The History of Psychedelic Mushrooms
1.1. Shamanic Practices and Rituals
Psychedelic mushrooms have a long history of use in shamanic and spiritual rituals. In Central America, mushrooms of the Psilocybe genus were considered sacred by the Aztecs, who called them "teonanácatl," or "flesh of the gods."
These mushrooms were consumed during religious ceremonies to communicate with spirits or to receive prophetic visions. Shamans, or curanderos, used these mushrooms to diagnose illnesses, heal the sick, and communicate with the spirit world.
1.2. Uses of the Fly Agaric
The fly agaric (Amanita muscaria), another psychoactive mushroom, has been used in shamanic rituals in Siberia and parts of Europe. Unlike psilocybin mushrooms, the fly agaric contains muscimol and ibotenic acid, which produce very different hallucinogenic effects.
The fly agaric (Amanita muscaria) is a psychoactive mushroom that has been used for centuries in shamanic rituals in Siberia and parts of Europe. Unlike psilocybin mushrooms, this mushroom contains muscimol and ibotenic acid, compounds that produce very different hallucinogenic effects.
In Siberian traditions, shamans consumed the fly agaric to enter a trance, communicate with spirits, and access altered states of consciousness. Controversial theories, such as those proposed by Aleister Crowley and Robert Gordon Wasson, even suggest that this mushroom may be the origin of the Vedic myth of soma, a sacred drink in ancient Indo-European cultures.
Medicinal Potential and Use in Microdoses
Recently, interest in the fly agaric has been reignited due to its potential benefits when used in microdoses. Microdosing involves ingesting a very small amount of muscimol, enough to experience its effects without causing hallucinations. Testimonials suggest that this practice may help improve mood, reduce anxiety, and even alleviate certain symptoms of neurological disorders. (See references below.)
However, it is crucial to emphasize that this practice must be carried out with great caution and under the supervision of specialists, as improper dosing can lead to serious adverse effects.
It is also important to note that the fly agaric is not edible without proper preparation. Its use requires extensive expertise, and consuming it without proper preparation can pose serious health risks. Therefore, we strongly advise against eating it without taking the necessary precautions.
1.3. The Introduction of Psychedelic Mushrooms to the West
The West first learned about psychedelic mushrooms largely through the ethnobotanist R. Gordon Wasson, who popularized their use after meeting Maria Sabina, a Mazatec shaman from Mexico, in 1955.
His research caught the attention of scientists and artists, ushering in a new era of psychedelic exploration in the 1960s. Since then, psychedelic mushrooms have been the subject of numerous scientific studies aimed at understanding their effects on the brain and their therapeutic potential.
2. Uses and Effects of Psychedelic Mushrooms
2.1. Neurobiological Mechanisms of Action
When ingested, psilocybin is rapidly converted into psilocin, the active form that primarily acts on serotonin 5-HT2A receptors in the brain. This interaction triggers a series of changes in sensory and cognitive perception.
Psilocin appears to promote increased connectivity between different regions of the brain, while simultaneously reducing activity in the default mode network (DMN), an area associated with self-awareness and rumination.
This reduction in DMN activity is often associated with experiences of ego dissolution, in which the boundaries between the self and the outside world become blurred.
2.2. Neuroplasticity and Brain Repair
Studies have shown that psilocybin can stimulate neuroplasticity—that is, the brain’s ability to form new synaptic connections and reorganize itself.
For example, a study published in the journal *Neuron* in 2019 demonstrated that psilocybin can promote dendritic growth and increase the density of neural connections, suggesting potential for repairing brain circuits damaged by chronic mental illnesses such as depression.
2.3. Psychological and Spiritual Effects
The psychological effects of psilocybin can vary considerably depending on the dose, the environment, and the user’s state of mind—concepts often summarized by the terms “set and setting.” At low doses, it can cause mild sensory distortions, heightened perception of colors and shapes, and increased introspection.
At higher doses, users may experience visual and auditory hallucinations, a profound distortion of reality, and experiences of ego dissolution.
These experiences can be spiritual and introspective, allowing individuals to reconnect with buried emotions or broader existential concepts.
Studies have shown that these experiences can lead to lasting changes in one’s outlook on life, a reduction in anxiety about death, and a sense of oneness with the universe.
3. Recent Research on Psilocybin and Mental Health
3.1. Treatment of Depression
Research into the use of psilocybin for treating depression that is resistant to conventional treatments is among the most promising. Clinical studies, particularly those conducted by Dr. Robin Carhart-Harris at Imperial College London, have shown that psilocybin, administered under medical supervision, can lead to a rapid and sustained reduction in depressive symptoms in patients with major depression.
For example, a study published in 2021 in *The New England Journal of Medicine* compared the effectiveness of psilocybin to that of traditional antidepressants and found that psilocybin was just as effective—or even more so—for some patients.
3.2. Addiction Treatment
Psilocybin also shows considerable potential in the treatment of addiction.
Research, including studies conducted by Dr. Matthew Johnson at Johns Hopkins University, has shown that psilocybin can help break the compulsive thought patterns associated with addiction to substances such as alcohol, tobacco, and opioids.
A 2014 study found that 80% of participants in a nicotine addiction treatment program that included psilocybin sessions remained abstinent six months after treatment.
These results are particularly promising given the often low success rates of traditional treatment methods.
3.3. Ongoing and Future Clinical Trials
Clinical trials involving psilocybin continue to increase worldwide.
In addition to treating depression and addiction, studies are exploring its potential for treating other mental health conditions, such as post-traumatic stress disorder (PTSD), anxiety disorders, and obsessive-compulsive disorder (OCD).
For example, an ongoing trial at the Yale School of Medicine is examining the effectiveness of psilocybin in treating anxiety among patients with terminal cancer, with the aim of reducing the existential anxiety associated with death.
4. Paul Stamets' "Stack" and Synergy with Lion's Mane
Paul Stamets, a world-renowned mycologist, has proposed a protocol called the "Stamets Stack," which combines microdoses of psilocybin with mushrooms such as Lion's Mane (Hericium erinaceus) and niacin (vitamin B3).
This "stack" is designed to maximize the neurogenic effects of mushrooms and improve neural connectivity.
Lion's Mane is a non-psychoactive mushroom known for its neuroprotective properties and its ability to stimulate the production of NGF (nerve growth factor), a protein essential for the development and survival of neurons.
By combining psilocybin with Lion's Mane, Stamets suggests that this synergy could potentially enhance neuroplasticity and promote brain healing following trauma or addiction.
Research on the "Stamets Stack" is still in its early stages, but the initial results are promising. Ongoing studies are examining the effectiveness of this approach in improving cognitive function and brain resilience, particularly in individuals with neurodegenerative disorders such as Alzheimer's disease.
5. Legislation and Ethics in France and Belgium
5.1. Legislation in France
In France, psilocybin has been classified as a narcotic since 2005, making its possession, production, and use illegal. Although there is ongoing discussion about the possible reintroduction of psilocybin for therapeutic purposes, current legislation remains strict.
However, calls are beginning to be made to review these laws, particularly in light of growing scientific evidence demonstrating the effectiveness of psilocybin in treating certain mental health conditions.
Organizations such as the French Psychedelic Societyare advocating for greater recognition of the therapeutic uses of psychedelic substances and for a reassessment of current legislation.
5.2. Legislation in Belgium
Belgium has a similar stance to France’s, with strict laws prohibiting the use of mushrooms containing psilocybin.
However, as in France, the debate over the medical use of psychedelic substances is beginning to gain momentum, fueled by promising results from international studies.
Research groups and health organizations, such as the Psychedelic Society Belgium, are calling for a reassessment of current laws, particularly regarding controlled medical use.
5.3. Legislation in Switzerland
Switzerland is adopting a more flexible approach to psychedelic substances, particularly for medical research. Psilocybin is classified as a controlled substance, but it may be used in scientific and therapeutic research settings under strictly regulated conditions.
Swiss hospitals and clinics are authorized to use psilocybin in clinical trials to explore its potential for treating mental health conditions such as treatment-resistant depression.
This makes Switzerland one of the most advanced European countries in terms of integrating psilocybin into medical practice.
5.4. Legislation in the Rest of Europe
The rest of Europe has a varied legal landscape when it comes to psilocybin and other psychedelics. In the Netherlands, the sale of psilocybin-containing truffles is legal, although the mushrooms themselves have been banned since 2008.
This exception has allowed the country to become a hub for guided psychedelic retreats, where truffles are used legally under professional supervision.
In Germany, psilocybin is classified as a controlled substance, but research is being conducted under strictly regulated protocols.
In Spain, although the cultivation of psilocybin-containing mushrooms is illegal, personal use in private settings is tolerated, creating a legal gray area.
In Eastern Europe, laws are generally stricter, with a total ban on psilocybin in most countries. However, some countries, such as the Czech Republic, take a more liberal approach to personal possession, although sale and distribution remain illegal.
5.4. Other examples from around the world:
- United States (Oregon): In November 2020, Oregon became the first U.S. state to legalize the medical use of psilocybin, allowing its use under supervision to treat mental health conditions such as treatment-resistant depression.
- United States (Colorado): In November 2022, Colorado legalized the medical use of psilocybin, joining Oregon in allowing supervised psychedelic treatments for patients with mental health conditions.
- Australia: In July 2023, Australia became the first country to legalize the use of psilocybin and MDMA to treat severe mental health conditions, such as treatment-resistant depression and post-traumatic stress disorder, under the supervision of licensed psychiatrists.
- Canada: Since 2020, Canada has authorized the medical use of psilocybin under special exemptions granted by Health Canada, primarily for terminally ill patients or those suffering from severe psychological disorders.
- Jamaica: Although psilocybin is not officially legal in Jamaica, its medicinal use is widely tolerated, and the country has become a popular destination for therapeutic psychedelic retreats.
- Brazil: In Brazil, the absence of laws specifically prohibiting psilocybin effectively allows for its implicit legalization, with psychedelic mushrooms often used in religious and therapeutic contexts.
- Portugal: Since the decriminalization of drugs in 2001, Portugal has permitted the use of psilocybin for medical purposes under medical supervision, incorporating this substance into a public health approach focused on treatment rather than repression.
- Costa Rica: Although not formally legalized, the medicinal use of psilocybin mushrooms is tolerated in Costa Rica, particularly at retreats and therapeutic centers that attract an international clientele seeking alternative treatments.
5.5. Ethical Debates
The use of psychedelic mushrooms raises complex ethical questions, particularly regarding their safety, regulation, and potential impact on society.
Although recent research is promising, it is crucial to ensure that these substances are used safely and under controlled conditions to minimize the risk of psychological dependence or other adverse effects.
Another ethical consideration concerns equitable access to these treatments. If psilocybin and other psychedelics are approved for medical use, it will be essential to ensure that these therapies are accessible to everyone, not just those who can afford them or who live in jurisdictions where these substances are legal.
6. Scientific and Technological Innovations
6.1. Advances in Biotechnology
Advances in biotechnology now make it possible to synthesize safer or more specific forms of psilocybin, or to create analogues that lack hallucinogenic effects but offer the same therapeutic benefits.
Companies such as Compass Pathways and the Usona Institute are at the forefront of these developments, seeking to develop psychedelic medications that could be marketed to treat a variety of mental health conditions.
6.2. The Role of Brain Imaging
The use of advanced brain imaging techniques, such as functional MRI (fMRI), has enabled scientists to study the effects of psychedelics on the brain in real time.
These techniques demonstrate how psilocybin alters connectivity between different regions of the brain and reduces activity in the default mode network (DMN), providing visual evidence of the neurobiological changes underlying the observed psychological and therapeutic effects.
7. Societal and Cultural Impact
7.1. Shift in Public Perception
It is interesting to note how public perceptions of psychedelic substances have evolved. Once stigmatized and associated with the countercultures of the 1960s, these substances are now being reevaluated from a scientific and therapeutic perspective.
Documentaries like *Fantastic Fungi* and books such as Michael Pollan’s *How to Change Your Mind* have played a key role in this rehabilitation, raising public awareness of the therapeutic potential of psychedelics.
7.2. Influence on Culture and Spirituality
The reintroduction of psychedelics into modern society is also influencing spiritual practices and healing communities. Psychedelic retreats led by therapists or modern shamans are becoming increasingly popular, offering safe spaces to explore altered states of consciousness.
This psychedelic renaissance can also be seen as a return to ancient spiritual practices, in which psychedelics were used as sacred tools to explore the mysteries of the mind and the universe.
8. Risks and Controversies
8.1. Potential Risks
Although psychedelics, such as psilocybin, show promising therapeutic potential, it is crucial to recognize that they are not without risks.
One of the most commonly cited risks is that of "bad trips"—potentially negative, even terrifying experiences that can occur while under the influence of these substances. These episodes may include feelings of intense fear, confusion, and despair, and can be exacerbated by a stressful environment or an unstable state of mind (the concept of "set and setting" is fundamental here). Certain YouTube channels cover this topic, notably “La gazette de l’abîme,” particularly this videoon the subject of bad trips.
Another significant risk is the re-triggering of traumatic experiences. Psychedelics can cause users to relive painful memories or buried traumas, which can be therapeutic in a controlled clinical setting but potentially destabilizing without proper supervision. This can lead to panic attacks or episodes of acute anxiety.
Unlike substances such as alcohol or tobacco, which carry a high risk of physical dependence, psychedelics do not cause physical dependence. However, there is a potential for psychological dependence, in which the user may become overly attached to the experiences or insights gained while under the influence of these substances.
In terms of comparative risk, psychedelics are, however, recognized as being significantly less harmful than legal substances such as alcohol or tobacco. Alcohol is associated with a high risk of physical dependence, organ damage (such as liver disease), and risky behaviors, while tobacco is one of the leading causes of preventable diseases worldwide, including lung cancer and cardiovascular disease.
In contrast, psychedelics such as psilocybin have a lower risk profile in terms of physical toxicity and mortality. A study published in *The Lancet* even ranked psilocybin among the least dangerous drugs in terms of harm to users and society.
Figure 2: Drugs ranked by their overall harm scores, showing the distinct contributions to the overall scores from harm to users and harm to others.(Source: The Lancet)
However, this does not mean that psychedelics are safe. The long-term effects of frequent use are not yet fully understood, and studies are currently underway to explore the potential neuropsychological consequences of their use. Furthermore, rare but real psychotic episodes have been documented in individuals predisposed to mental health disorders, underscoring the importance of a prior evaluation by a healthcare professional.
In summary, while psychedelics may offer significant therapeutic benefits, their use must be supervised by qualified professionals in safe environments, following a prior assessment of individual risks.
Self-medication without careful consideration of "set and setting" is not recommended, as it significantly increases the risk of serious side effects.
8.2. Ethical Controversies
Ethical debates surrounding psychedelics include concerns about the commercialization of these substances, respect for Indigenous traditions, and questions regarding informed consent in clinical studies.
Some experts fear that the rush toward psychedelics could lead to commercial exploitation that might overlook the spiritual and cultural aspects of these substances, or even endanger the indigenous communities that have preserved this knowledge for centuries.
9. Long-Term Outlook
9.1. Impact on Health Care Systems
If psychedelics continue to demonstrate their effectiveness in treating mental health disorders, they could have a significant impact on healthcare systems by reducing the burden of chronic diseases and offering new treatment options.
The costs of mental health care are exorbitant, and the introduction of psychedelic-based therapies could potentially reduce these costs while improving patient outcomes.
9.2. Future Scientific Developments
Future directions in psychedelic research will likely include larger and more diverse studies, investigations into specific mechanisms of action, and the development of new psychedelic analogues.
The research will also focus on the long-term effects of psychedelic use, as well as on optimizing treatment protocols to maximize benefits while minimizing risks.
10. Recognized Scientific References
For further reading on the topics covered in this article, here is a list of scientific and academic references that served as the basis for this article:
-
Carhart-Harris, R. L., et al. (2016). "Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study." The Lancet Psychiatry.
- Griffiths, R. R., et al. (2006). "Psilocybin can induce mystical-type experiences that have substantial and lasting personal meaning and spiritual significance." Psychopharmacology.
- Johnson, M. W., et al. (2014). "Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction." Journal of Psychopharmacology.
- Stamets, P. (2020). Fantastic Fungi: How Mushrooms Can Heal, Shift Consciousness, and Save the Planet.
- Pollan, M. (2018). How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence.
- Majić, T., Schmidt, T. T., & Gallinat, J. (2015). "Psychedelic drugs and the central nervous system: a clinical review of mechanisms, effects, and therapeutic potential." Journal of Neurotherapy.
- Chambon, O. (2015). Psychedelics in Psychotherapy: A Revolution in the Making? Albin Michel.
- Suntay, T. A. (2022). Microdosing with Amanita Muscaria: Creativity, Healing, and Recovery with the Sacred Mushroom. Inner Traditions.
- Williams, D. (2020). Fly Agaric: A Compendium of History, Pharmacology, Mythology, & Exploration. Psychedelic Press.
- Dupuis, D. (2021). Hallucinogenic Mushrooms: An Ethnography of Contemporary Use. Petra Publishing.
